These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

375 related items for PubMed ID: 14560928

  • 1. Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats.
    Zhang H, Yao M, Morrison RA, Chong S.
    Arch Pharm Res; 2003 Sep; 26(9):768-72. PubMed ID: 14560928
    [Abstract] [Full Text] [Related]

  • 2. Montmorillonite-surfactant hybrid particles for modulating intestinal P-glycoprotein-mediated transport.
    Nielsen RB, Kahnt A, Dillen L, Wuyts K, Snoeys J, Nielsen UG, Holm R, Nielsen CU.
    Int J Pharm; 2019 Nov 25; 571():118696. PubMed ID: 31525443
    [Abstract] [Full Text] [Related]

  • 3. Tween 20 increases intestinal transport of doxorubicin in vitro but not in vivo.
    Al-Saraf A, Holm R, Nielsen CU.
    Int J Pharm; 2016 Feb 10; 498(1-2):66-9. PubMed ID: 26685728
    [Abstract] [Full Text] [Related]

  • 4. Digestion of surfactants does not affect their ability to inhibit P-gp-mediated transport in vitro.
    Rasmussen AJ, Pedersen M, Griffin BT, Holm R, Nielsen CU.
    Int J Pharm; 2024 May 10; 656():124120. PubMed ID: 38621613
    [Abstract] [Full Text] [Related]

  • 5. The application of P-gp inhibiting phospholipids as novel oral bioavailability enhancers - An in vitro and in vivo comparison.
    Weinheimer M, Fricker G, Burhenne J, Mylius P, Schubert R.
    Eur J Pharm Sci; 2017 Oct 15; 108():13-22. PubMed ID: 27590127
    [Abstract] [Full Text] [Related]

  • 6. Role of P-glycoprotein in the intestinal absorption of tanshinone IIA, a major active ingredient in the root of Salvia miltiorrhiza Bunge.
    Yu XY, Lin SG, Zhou ZW, Chen X, Liang J, Liu PQ, Duan W, Chowbay B, Wen JY, Li CG, Zhou SF.
    Curr Drug Metab; 2007 May 15; 8(4):325-40. PubMed ID: 17504222
    [Abstract] [Full Text] [Related]

  • 7. Effect of saquinavir/ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe.
    Schmitt C, Kaeser B, Riek M, Bech N, Kreuzer C.
    Int J Clin Pharmacol Ther; 2010 Mar 15; 48(3):192-9. PubMed ID: 20197013
    [Abstract] [Full Text] [Related]

  • 8. Polysorbate 20 increases oral absorption of digoxin in wild-type Sprague Dawley rats, but not in mdr1a(-/-) Sprague Dawley rats.
    Nielsen CU, Abdulhussein AA, Colak D, Holm R.
    Int J Pharm; 2016 Nov 20; 513(1-2):78-87. PubMed ID: 27601334
    [Abstract] [Full Text] [Related]

  • 9. Ex vivo and in vivo investigations of the effects of extracts of Vernonia amygdalina, Carica papaya and Tapinanthus sessilifolius on digoxin transport and pharmacokinetics: assessing the significance on rat intestinal P-glycoprotein efflux.
    Oga EF, Sekine S, Horie T.
    Drug Metab Pharmacokinet; 2013 Nov 20; 28(4):314-20. PubMed ID: 23291634
    [Abstract] [Full Text] [Related]

  • 10. Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients.
    Yamagata T, Kusuhara H, Morishita M, Takayama K, Benameur H, Sugiyama Y.
    Drug Metab Dispos; 2007 Jul 20; 35(7):1142-8. PubMed ID: 17446265
    [Abstract] [Full Text] [Related]

  • 11. Nonionic surfactants increase digoxin absorption in Caco-2 and MDCKII MDR1 cells: Impact on P-glycoprotein inhibition, barrier function, and repeated cellular exposure.
    Al-Ali AAA, Steffansen B, Holm R, Nielsen CU.
    Int J Pharm; 2018 Nov 15; 551(1-2):270-280. PubMed ID: 30240828
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of the Role of P-glycoprotein (P-gp)-Mediated Efflux in the Intestinal Absorption of Common Substrates with Elacridar, a P-gp Inhibitor, in Rats.
    Suzuki K, Taniyama K, Aoyama T, Watanabe Y.
    Eur J Drug Metab Pharmacokinet; 2020 Jun 15; 45(3):385-392. PubMed ID: 32078103
    [Abstract] [Full Text] [Related]

  • 13. In silico modeling for the nonlinear absorption kinetics of UK-343,664: a P-gp and CYP3A4 substrate.
    Abuasal BS, Bolger MB, Walker DK, Kaddoumi A.
    Mol Pharm; 2012 Mar 05; 9(3):492-504. PubMed ID: 22264132
    [Abstract] [Full Text] [Related]

  • 14. Effects of Fostamatinib on the Pharmacokinetics of Digoxin (a P-Glycoprotein Substrate): Results From in Vitro and Phase I Clinical Studies.
    Martin P, Gillen M, Millson D, Oliver S, Brealey C, Elsby R, Baluom M, Lau D, Mant T.
    Clin Ther; 2015 Dec 01; 37(12):2811-22. PubMed ID: 26514315
    [Abstract] [Full Text] [Related]

  • 15. Effects of Rolapitant Administered Intravenously or Orally on the Pharmacokinetics of Digoxin (P-glycoprotein Substrate) and Sulfasalazine (Breast Cancer Resistance Protein Substrate) in Healthy Volunteers.
    Wang X, Zhang ZY, Arora S, Hughes L, Wang J, Powers D, Christensen J, Lu S, Kansra V.
    J Clin Pharmacol; 2018 Feb 01; 58(2):202-211. PubMed ID: 28906558
    [Abstract] [Full Text] [Related]

  • 16. Application of Intestinal Epithelial Cells Differentiated from Human Induced Pluripotent Stem Cells for Studies of Prodrug Hydrolysis and Drug Absorption in the Small Intestine.
    Akazawa T, Yoshida S, Ohnishi S, Kanazu T, Kawai M, Takahashi K.
    Drug Metab Dispos; 2018 Nov 01; 46(11):1497-1506. PubMed ID: 30135242
    [Abstract] [Full Text] [Related]

  • 17. High-dose etoposide formulations do not saturate intestinal P-glycoprotein: Development, stability, and pharmacokinetics in Sprague-Dawley rats.
    Al-Ali AAA, Sandra L, Versweyveld D, Pijpers I, Dillen L, Vermeulen A, Snoeys J, Holm R, Nielsen CU.
    Int J Pharm; 2020 Jun 15; 583():119399. PubMed ID: 32376439
    [Abstract] [Full Text] [Related]

  • 18. Dabigatran Etexilate and Digoxin: Comparison as Clinical Probe Substrates for Evaluation of P-gp Inhibition.
    Chu X, Galetin A, Zamek-Gliszczynski MJ, Zhang L, Tweedie DJ, International Transporter Consortium.
    Clin Pharmacol Ther; 2018 Nov 15; 104(5):788-792. PubMed ID: 30238965
    [No Abstract] [Full Text] [Related]

  • 19. Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes.
    Penzak SR, Shen JM, Alfaro RM, Remaley AT, Natarajan V, Falloon J.
    Ther Drug Monit; 2004 Jun 15; 26(3):322-30. PubMed ID: 15167636
    [Abstract] [Full Text] [Related]

  • 20. Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions.
    Elsby R, Surry DD, Smith VN, Gray AJ.
    Xenobiotica; 2008 Jul 15; 38(7-8):1140-64. PubMed ID: 18668443
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.